In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

CSL raises $A1.7bn for purchase of Talecris

Executive Summary

Australia's CSL (vaccines) completed an $A1.7bn ($1.5bn) private equity sale to institutional investors. The company issued 47.5mm ordinary shares at $A36.75 each (a slight premium) to finance its recently announced $3.1bn purchase of Talecris (hemostasis, pulmonology, and immune disorder therapeutics).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies